Podcast appearances and mentions of brian kaspar

Brian Kaspar discusses the role of astrocyte cells in the motor neuron disease ALS.

Wednesday, April 10, 2019 Brian Kaspar (AveXis Inc) talks about the realities and promise of building a single-dose gene transfer therapy for treating the prime gene defect in spinal muscular atrophy (SMA) type I. He discusses his company's modified adeno-associated virus 9 approach to human gene therapy that is currently in highly promising clinical trials, for SMA, and in development for Rett syndrome and one variant of Amyotrophic Lateral Sclerosis. Duration: 45 minutes Discussants:(in alphabetical order) Jenny Hsieh (Semmes Foundation Chair, UTSA) Salma Quraishi (Res Asst Prof, UTSA) Charles Wilson (Ewing Halsell Chair, UTSA) acknowledgement: JM Tepper for original music.

Brian Kaspar (AveXis Inc) talks about the realities and promise of building a single dose gene transfer therapy for treating the prime gene defect in spinal muscular atrophy (SMA) type I. He discusses his company’s modified adeno-associated virus 9 approach to human gene therapy that is currently in highly promising clinical trials, for SMA, and in development for Rett syndrome and one variant of Amyotropic Lateral Sclerosis. Duration: 45 minutesDiscussants:(in alphabetical order)Jenny Hsieh (Semmes Foundation Chair, UTSA)Salma Quraishi (Res Asst Prof, UTSA)Charles Wilson (Ewing Halsell Chair, UTSA)acknowledgement: JM Tepper for original music.

Brian Kaspar discusses the role of astrocyte cells in the motor neuron disease ALS.

Dr. Brian Kaspar Discusses a New Method for Studying ALS, with Potential to Test Therapeutics in Individual Patients :: April 2014 Guest: Brian Kaspar, PhD, is a principal investigator in the Center for Gene Therapy and the first recipient of the Grant Morrow, III, MD, Endowed Chair in Pediatric Research in The Research Institute at Nationwide Children’s Hospital. He is also an associate professor in the departments of Pediatrics and Neuroscience at The Ohio State University College of Medicine, and a recognized national expert in the discovery of new therapies for spinal muscular atrophy and amyotrophic lateral sclerosis.

Dr. Brian Kaspar Discusses a New Method for Studying ALS, with Potential to Test Therapeutics in Individual Patients :: April 2014 Guest: Brian Kaspar, PhD, is a principal investigator in the Center for Gene Therapy and the first recipient of the Grant Morrow, III, MD, Endowed Chair in Pediatric Research in The Research Institute at Nationwide Children’s Hospital. He is also an associate professor in the departments of Pediatrics and Neuroscience at The Ohio State University College of Medicine, and a recognized national expert in the discovery of new therapies for spinal muscular atrophy and amyotrophic lateral sclerosis.

Guest: Brian Kaspar, PhD, Nationwide Children's Hospital Access an abstract of this Month's Featured Research Article: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010 Mar;28(3):271-4.

Guest: Brian Kaspar, PhD, Nationwide Children's Hospital Access an abstract of this Month's Featured Research Article: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010 Mar;28(3):271-4.